Conocimiento de la ley y preparación del personal sanitario sobre el proceso asistencial de la muerte.

The aims of this study were to ascertain the perception that health professionals (doctors, nurses and nursing assistants) have about their preparation for the care of terminally ill patients and to determine their knowledge about palliative care legislation. This cross sectional study was performed at a hospital in Granada (Spain); we administered an ad hoc questionnaire. The results indicated that although most of the staff had worked with terminally ill patients, only half believed that they have been trained to care for them. A significant proportion stated that they did not know about the current palliative care legislation. Most professionals would question the withdrawal of therapies for the maintenance of life; most of them are also unaware of the mechanism for reporting on the completion of a Living Will, as well as a Plan for Palliative Care in Andalusia (Spain).

Art i Baix Ter : artistes actuals i paisatge

Aquest projecte de recerca proposa un estudi emmarcat en la realitat actual de lazona geogràfica del Baix Ter enfocat des d’un prisma transversal que col·labori a feraflorar noves reflexions sobre el territori i el paisatge a partir d’algunes de les aportacionsque s’estan produint des de les arts plàstiques.La investigació pretén omplir un buit historiogràfic existent pel que fa alpatrimoni d’art contemporani de la zona, tenint en compte la notorietat de la sevariquesa cultural i artística. Es proposa analitzar algunes de les figures artístiques mésrellevants que hi treballen i seleccionar d’aquelles que treballin més directament sobre elterritori, el paisatge i la formació de nous valors al seu entorn

Trends in self-reported past alcoholic beverage consumption and ethanol intake from 1950 to 1995 observed in eight European countries participating in the European Investigation into Cancer and Nutrition (EPIC).

OBJECTIVE To describe the trends of self-reported past consumption of alcoholic beverages and ethanol intake from 1950 to 1995 within the European Prospective Investigation into Cancer and Nutrition (EPIC). DESIGN Data on consumption of beer/cider, wine and liqueur/spirits were obtained retrospectively at age 20, 30 and 40 years to calculate average consumption and ethanol intake for the time periods 1950-1975 (at age 20), 1960-1985 (at age 30) and 1970-1995 (at age 40). Regression analysis was conducted with the time period data to assess trends in past alcoholic beverage consumption and ethanol intake with time. SETTING The EPIC project. SUBJECTS In total, 392 064 EPIC participants (275 249 women and 116 815 men) from 21 study centres in eight European countries. RESULTS Generally, increases in beer/cider consumption were observed for most EPIC centres for 1950-1975, 1960-1985 and 1970-1995. Trends in wine consumption differed according to geographical location: downward trends with time were observed for men in southern European EPIC centres, upward trends for those in middle/northern European study centres. For women, similar but less pronounced trends were observed. Because wine consumption was the major contributor to ethanol intake for both men and women in most study centres, time trends for ethanol intake showed a similar geographical pattern to that of wine consumption. CONCLUSION The different trends in alcoholic beverage consumption and ethanol intake suggest that information depicting lifetime history of ethanol intake should be included in analyses of the relationship between ethanol and chronic diseases, particularly in multi-centre studies such as EPIC.

Objets d'art, curiosités et tableaux composant la précieuse collection de M. ***... [de Norzy, agent de change] / [expert] Roussel

[Vente. Art. 1860-03-12. Paris]

Objets d'art, curiosités et tableaux composant la précieuse collection de M. ***... [de Norzy, agent de change] / [expert] Roussel

[Vente. Art. 1860-03-12. Paris]

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

The definition of a biomarker provided by the World Health Organization is any substance, structure, or process that can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. Currently, the lack of prognosis and progression markers for chronic Chagas disease has posed limitations for testing new drugs to treat this neglected disease. Several molecules and techniques to detect biomarkers inTrypanosoma cruzi-infected patients have been proposed to assess whether specific treatment with benznidazole or nifurtimox is effective. Isolated proteins or protein groups from different T. cruzistages and parasite-derived glycoproteins and synthetic neoglycoconjugates have been demonstrated to be useful for this purpose, as have nucleic acid amplification techniques. The amplification of T. cruziDNA using the real-time polymerase chain reaction method is the leading test for assessing responses to treatment in a short period of time. Biochemical biomarkers have been tested early after specific treatment. Cytokines and surface markers represent promising molecules for the characterisation of host cellular responses, but need to be further assessed.

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.

INTRODUCTION Due to their low CNS penetrance, there are concerns about the capacity of non-conventional PI-based ART (monotherapy and dual therapies) to preserve neurocognitive performance (NP). METHODS We evaluated the NP change of aviremic participants of the SALT clinical trial (1) switching therapy to dual therapy (DT: ATV/r+3TC) or triple therapy (TT: ATV/r+2NRTI) who agreed to perform an NP assessment (NPZ-5) at baseline and W48. Neurocognitive impairment and NP were assessed using AAN-2007 criteria (2) and global deficit scores (GDS) (3). Neurocognitive change (GDS change: W48 - baseline) and the effect of DT on NP evolution crude and adjusted by significant confounders were determined using ANCOVA. RESULTS A total of 158 patients were included (Table 1). They had shorter times because HIV diagnosis, ART initiation and HIV-suppression and their virologic outcome at W48 by snapshot was higher (79.1% vs 72.7%; p=0.04) compared to the 128 patients not included in the sub-study. By AAN-2007 criteria, 51 patients in each ART group (68% vs 63%) were neurocognitively impaired at baseline (p=0.61). Forty-seven patients were not reassessed at W48: 30 lost of follow-up (16 DT-14 TT) and 17 had non-evaluable data (6 DT-11 TT). Patients retested were more likely to be men (78.9% vs 61.4%) and had neurological cofounders (9.6% vs 0%) than patients non-retested. At W48, 3 out of 16 (5.7%) patients on DT and 6 out of 21 (10.5%) on TT who were non-impaired at baseline became impaired (p=0.49) while 10 out of 37 (18.9%) on DT and 7 out of 36 (12.3%) on TT who were neurocognitively impaired at baseline became non-impaired (p=0.44). Mean GDS changes (95% CI) were: Overall -0.2 (-0.3 to -0.04): DT -0.26 (-0.4 to -0.07) and TT -0.08 (-0.2 to 0.07). NP was similar between DT and TT (0.15). This absence of differences was also observed in all cognitive tests. Effect of DT: -0.16 [-0.38 to 0.06]) (r(2)=0.16) on NP evolution was similar to TT (reference), even after adjusting (DT: -0.11 [-0.33 to 0.1], TT: reference) by significant confounders (geographical origin, previous ATV use and CD4 cell count) (r(2)=0.25). CONCLUSIONS NP stability was observed after 48 weeks of follow up in the majority of patients whether DT or TT was used to maintain HIV-suppression. Incidence rates of NP impairment or NP impairment recovery were also similar between DT and TT.

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.

INTRODUCTION Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1). Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control (2). The aim of this study was to analyze lipid changes in HIV-patients at 24 weeks after switching to Eviplera® (emtricitabine/RPV/tenofovir disoproxil fumarate [FTC/RPV/TDF]). MATERIALS AND METHODS Retrospective, multicentre study of a cohort of asymptomatic HIV-patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors (NRTI)+protease inhibitor (PI)/non nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir boosted PI monotherapy to Eviplera® during February-December, 2013; all had undetectable HIV viral load for ≥3 months prior to switching. Patients with previous failures on antiretroviral therapy (ART) including TDF and/or FTC/3TC, with genotype tests showing resistance to components of Eviplera®, or who had changed the third drug of the ART during the study period were excluded. Changes in lipid profile and cardiovascular risk (CVR), and efficacy and safety at 24 weeks were analyzed. RESULTS Among 305 patients included in the study, 298 were analyzed (7 cases were excluded due to lack of data). Men 81.2%, mean age 44.5 years, 75.8% of HIV sexually transmitted. 233 (78.2%) patients switched from a regimen based on 2 NRTI+NNRTI (90.5% EFV/FTC/TDF). The most frequent reasons for switching were central nervous system (CNS) adverse events (31.0%), convenience (27.6%) and metabolic disorders (23.2%). At this time, 293 patients have reached 24 weeks: 281 (95.9%) have continued Eviplera®, 6 stopped it (3 adverse events, 2 virologic failures, 1 discontinuation) and 6 have been lost to follow up. Lipid profiles of 283 cases were available at 24 weeks and mean (mg/dL) baseline vs 24 weeks are: total cholesterol (193 vs 169; p=0.0001), HDL-c (49 vs 45; p=0.0001), LDL-c (114 vs 103; p=0.001), tryglycerides (158 vs 115; p=0.0001), total cholesterol to HDL-c ratio (4.2 vs 4.1; p=0.3). CVR decreased (8.7 vs 7.5%; p= 0.0001). CD4 counts were similar to baseline (653 vs 674 cells/µL; p=0.08), and 274 (96.8%) patients maintained viral suppression. CONCLUSIONS At 24 weeks after switching to Eviplera®, lipid profile and CVR improved while maintaining a good immunovirological control. Most subjects switched to Eviplera® from a regimen based on NNRTI, mainly EFV/FTC/TDF. CNS adverse events, convenience and metabolic disorders were the most frequent reasons for switching.

Tendencias y fenómenos tecnológicos: Insights como técnica para aprender del pasado. Telecomunicaciones en España 1995-2006

El análisis retrospectivo de las causas y consecuencias de fenómenos tecnológicos y telecomunicativos y el hallazgo de los elementos o los parámetros que provocan que en situaciones y proyectos empresariales similares los resultados sean dispares es tarea científicamente compleja. A tal efecto, y ante la dificultad que entraña ese cometido, en esta investigación procedemos a aplicar la técnica de los insights como punto de partida para el desarrollo de productos tecnológicamente innovadores, que realmente pueden satisfacer las necesidades ocultas del consumidor. Como muestra, analizamos la aplicación de la técnica de los insights en un operador de telecomunicaciones y una apuesta tecnológica (Vodafone y la tecnología PLC) en la fase de desarrollo de las telecomunicaciones en España desde 1995 a 2006.

La tutela cautelar de les víctimes de violència de gènere

Aquest projecte de recerca té com a objecte l'anàlisi de les línies bàsiques de la Llei orgànica 1/2004, de 28 de desembre, de mesures de protecció integral contra la violència de gènere i, més concretament, de la regulació de la tutela cautelar de les víctimes d'aquest tipus de violència. Quant a la regulació de les mesures de protecció que podrà adoptar el Jutge de violència de gènere, s'ha optat per la seva inclusió expressa, ja que no es troben recollides com a mesures cautelars a la Llei d'enjudiciament criminal, que només regula la prohibició de residència i la de poder anar a un determinat lloc pels delictes recollits a l'art. 57 del Codi penal (article 544 bis LECrim, introduït per la Llei orgànica 14/1999). Malgrat els dubtes envers la naturalesa jurídica d'aquestes mesures, és clar que també persegueixen el fi típic de les mesures cautelars clàssiques, encara que de forma tangencial: assegurar el desenvolupament amb èxit del judici oral, mantenint allunyada a la víctima tan de nous actes violents com d'amenaces dirigides a assolir una retractació del seu inicial testimoni. Es tracta, doncs, de "mesures cautelars" (personals) que incideixen sobre la llibertat de l'imputat (restringint la seva llibertat de circulació i de residència), que tenen com a pressupostos tant el fumus boni iuris (judici de probabilitat del jutge), com el periculum in mora (entès més aviat com a periculum libertatis o periculum in damno), i que responen a les característiques d'instrumentalitat, provisionalitat, jurisdiccionalitat, oficialitat, revocabilitat i homogeneïtat (però no identitat) amb les mesures executives. D'altra banda, també s'afegeix la possibilitat que qualsevol d'aquestes mesures de protecció pugui ser utilitzada com a mesura de seguretat, des del principi o al llarg de l'execució de la sentència, incrementant-se així la llista de l'art. 105 del Codi penal, i possibilitant al jutge la garantia de protecció de les víctimes més enllà de la finalització del procés.

Reconeixement facial en obres d'art : avaluació del rendiment dels mètodes de l'estat de l'art actual

Aquest paper es divideix en 3 parts fonamentals, la primera relata el que pretén mostrar aquest estudi, que és aplicar els sistemes actuals de reconeixement facial en una base de dades d'obres d'art. Explica quins mètodes s'utilitzaran i perquè es interessant realitzar aquest estudi. La segona passa a mostrar el detall de les dades obtingudes en l'experiment, amb imatges i gràfics que facilitaran la comprensió. I en l'última part tenim la discussió dels resultats obtinguts en l'anàlisi i les seves posteriors conclusions.